Home » Authors » Don Long

Articles by Don Long

Piper Jaffray Health Care Conference: Boston Sci tackles challenge of product growth, execution

Jan. 26, 2005

ViaCell Prices At Low End, But Gets $52.5M In 2005's First IPO

Jan. 24, 2005

ViaCell Prices At Low End, But Gets $52.5M In 2005's First IPO

Jan. 24, 2005

SurModics acquires remaining portion of InnoRx for $4.1M

Jan. 20, 2005

International Symposium on Endovascular Therapy: Belgian researchers present 'absorbable' metal stent data

Jan. 20, 2005

JAMA report seen supporting market uptake for Cypher DES

Jan. 13, 2005

New LSA 'angels' firm will offer device and biotech support

Jan. 7, 2005

Chlorhexidine gluconate key aid in battle vs. catheter infections

Jan. 4, 2005

Demographics drive health help in plastic surgery, cardio arenas

Jan. 4, 2005

Angioplasty/stenting, keyhole bypass are combined in a 'first'

Jan. 1, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...